# Prohealbiologix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prohealbiologix

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.prohealpharma.com
- Latest round: Angel (Jan 22, 2020)
- Investors on record: 1

## About

Founded in 2019 and based in Suzhou, China, Prohealbiologix operates as a biopharmaceutical company that focuses on the production and sales of biomolecule drugs. Its team members come from pharmaceutical companies such as Allergan, Pfizer, and Johnson & Johnson. In August 2020, the company opened its R&D center in the Biomedical Industrial Park. It closed a pre-series A funding in 2021. Its IGF1-R antibody, PHP1003, received a clinical trial application in April 2022 from the NMPA (National Medical Products Administration). In June 2024, Prohealbiologix raised a strategic investment for CNY 40 million.

Prohealbiologix's main business is the research, development, production, and sales of innovative drugs in therapeutic areas such as ophthalmic diseases, immune diseases, and tumors. Its ophthalmic product lines include PHP1003 injection and PHP0101 eye drops, etc. The PHP1003 injection has entered Phase II clinical trials, which adopt the administered methods by subcutaneous injection. Products can be used in the treatment of presbyopia, retinopathy, and immune disorders.

The company generates revenue by providing biomolecule drugs in therapeutic areas.

The company will use the strategic investment for the development of the ophthalmic clinical drug pipeline.

## Funding rounds

- Angel, Jan 22, 2020 — GoldHold Wisdom Venture Capital

## Investors

- GoldHold Wisdom Venture Capital (https://capitalatlas.ai/funds/goldhold-wisdom-venture-capital) — Angel